Retrophin - TVTX Earnings per share for the last 12 months

Official company branding of Travere Corp (TVTX)

Travere Therapeutics (TVTX) shows growth in rolling trailing twelve-month net income per share driven by premium pricing for its innovative therapy. The value -59.00 indicates the current level of this metric. Business stability relies on an ethical corporate culture and the retention of key talent, although global logistical disruptions and sanctions limit access to certain foreign markets for drug distribution.

TVTX: Retrophin Net earnings per share (EPS TTM) 02/11/2024 - 11/18/2026

Financial and market metric breakdowns for Retrophin (TVTX)

Initial company analysis:Travere Therapeutics, Inc. TVTX
Core merchandise of Travere Therapeutics Inc

The revenue stability of Travere Therapeutics (TVTX) from rare kidney disease therapies is constrained by the dependence of profits on the scaling of new products. By analyzing the current EPS TTM YoY growth rate on the GURU.Markets platform, an investor assesses the rolling annual net profit trend, where daily data updates allow for the timely detection of deviations from the market consensus and the avoidance of overpaying for inflated expectations.